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Marseille, FranceObjectives This study was designed to deﬁne the hyperresponse to thienopyridine (very low on-
treatment platelet reactivity [VLTPR]) as the most predictive threshold value of platelet reactivity index
vasodilator-stimulated phosphoprotein (PRI VASP) for the prediction of non-access site–related
bleeding events. We also aimed to identify predictors of bleeding and VLTPR in patients treated with
thienopyridines.
Background New P2Y12 blockers and platelet monitoring has been proposed to optimize platelet
inhibition after acute coronary syndromes and improve ischemic outcomes. However, bleeding
complications remain the Achilles’ heel of antiplatelet therapy, and platelet monitoring could be useful
to evaluate this risk.
Methods A total of 1,542 consecutive patients undergoing coronary stenting for ACS were included in
the present study (287 taking clopidogrel 75 mg, 868 taking clopidogrel 150 mg, and 387 taking
prasugrel 10 mg).
Results During 6-month follow-up, 9% of patients (n ¼ 139) experienced nonaccess site–related
Bleeding Academic Research Consortium bleeding complications. These patients were more often
women and nondiabetic and had lower PRI VASP values than others (p < 0.001). Receiver-operating
characteristic curve analysis (0.71, p < 0.01) identiﬁed a threshold value for VLTPR of PRI VASP 10% to
predict bleeding events with a sensitivity of 17% and a speciﬁcity of 97%. Although prasugrel was the
main predictor of VLTPR in the whole population (odds ratio: 10.2, 95% conﬁdence interval: 3.0 to
–34.2; p < 0.001), VLTPR was the strongest and independent predictor of bleeding (odds ratio: 4.7, 95%
conﬁdence interval: 2.7 to 8.3; p < 0.001).
Conclusions The present study identiﬁed VLTPR (PRI VASP 10%) as the strongest predictor of
bleeding complications in patients treated with thienopyridines. This marker could be useful for
tailored therapy and bleeding prevention. (J Am Coll Cardiol Intv 2013;6:854–63) ª 2013 by the
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855Dual antiplatelet therapy with aspirin and clopidogrel has been systematically assessed during this consultation. The ethics
considered the gold standard therapy for patients undergoing
percutaneous coronary interventions (PCIs) and/or after acute
coronary syndromes (ACS) (1–3) before new P2Y12 blockers
demonstrated their clinical beneﬁt in large randomized,
controlled trials (4,5). Several biological studies have described
a broad interindividual variability of platelet response to clopi-
dogrel (6). The clinical relevance of platelet function testing has
been demonstrated in different clinical settings for both
ischemic (7–11) and bleeding (12,13) events with clopidogrel.
These recent ﬁndings clearly supported the need to optimizeSee page 864
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infarctionantiplatelet therapy and/or platelet function tests to identify low
responders as candidates for treatment adaptation. Several
studies have tested the beneﬁts of tailored andoptimized therapy
in patients with high on-treatment platelet reactivity with
different strategies including new P2Y12 blockers and hetero-
geneous results (14–18). These studies focused on prevention of
ischemic endpoints (14–18) without targeting a therapeutic
window to avoid both ischemic and bleeding events (14–18).
However, bleeding complications remain the Achilles’ heel of
antiplatelet therapy, and platelet monitoring could also be useful
to evaluate this risk. Recently, clinical studies showed an asso-
ciation between on-treatment platelet reactivity with prasugrel
and the occurrence of bleeding complications (19,20), con-
ﬁrming previous ﬁndings with clopidogrel regarding the rela-
tionship between platelet inhibition and bleeding risk (12,13).
Therefore, the present study was designed to deﬁne the hyper-
response to thienopyridine or very low on-treatment platelet
reactivity (VLTPR) as the most predictive threshold value of
platelet reactivity index vasodilator-stimulated phosphoprotein
(PRI VASP) for the prediction of bleeding events. We also
aimed to identify predictors of bleeding andVLTPR in patients
treated by different thienopyridine regimens after ACS.VLTPR = very low on-
treatment platelet reactivityMethods
Study population. Consecutive patients admitted for non–
ST-segment elevation ACS or ST-segment elevation
myocardial infarction (STEMI) in our institution were
eligible for this prospective study if they had undergone
successful PCI and were treated at discharge with clopidogrel
75 mg, clopidogrel 150 mg, or prasugrel 10 mg. All patients
discharged on clopidogrel received a 600-mg loading dose of
clopidogrel, and all patients on prasugrel received a 60-mg
loading dose. The exclusion criteria were a history of bleeding
diathesis, previous stroke or transient ischemic attack for
prasugrel therapy, contraindications to antiplatelet therapy,
platelet count<100 g/l and creatinine clearance<25ml/min.
Clopidogrel and prasugrel responses were assessed at
1-month clinical follow-up by PRI VASP. Adherence wascommittee of our institution approved the study protocol, and
patients gave written informed consent for participation.
Platelet parameters. Blood samples were drawn at 1-month
follow-up. For patients who experienced signiﬁcant bleeding
(Bleeding Academic Research Consortium [BARC] 2) and
who need to stop thienopyridine, platelet testing was performed
in our center before drug discontinuation. Blood was sent
immediately to the hemostasis laboratory to determine the
VASP phosphorylation state of whole blood. We used a stan-
dardized ﬂow cytometric assay (Platelet VASP; Diagnostica
Stago (Biocytex), Asnières, France), which is an adaptation of
the method of Schwarz et al. (21) previously described. PRI
VASP was calculated from the median ﬂuorescence intensity
(MFI) of samples incubated with prostaglandin E1 (PGE1) or
prostaglandin E1 and adenosine
diphosphate (ADP) according to
the formula: PRI VASP ¼
[(MFI(PGE1)  MFI(PGE1þADP)/
MFIPGE1]  100. High on-treat-
ment platelet reactivity (HTPR)
was deﬁned as PRI VASP >50%,
as previously proposed (14). We
decided to identify the best
threshold value to deﬁne VLTPR
from receiver-operating character-
istic (ROC) curve analysis testing
the relationship between bleeding
and PRI VASP.
Clinical follow-up. Clinical follow-
up was planned for all patients at
1 month and 6 months after
hospital dischargewith a clinic visit
and platelet function testing at 1
month only. The clinical endpoint
was the occurrence of bleeding
events according to the Academic
Bleeding Consensus Deﬁnitions
with type 1, 2, 3, or 5 (type 4 was
not expected because no patient had planned coronary artery
bypass grafting) (22). Although radial access is widely used in
our center and access-site bleeding less dependent on platelet
inhibition, we collected only the non-access–site bleeding
complications. Hard ischemic endpoints were also collected,
and the primary ischemic endpoint was occurrence of deﬁnite or
probable stent thrombosis.
Endpoints. The primary endpoints of the present study were
deﬁned as follows: 1) the incidence of non-access site–related
BARC bleeding complications, relationship with PRI VASP,
and predictors of bleedings in the whole population and in
different groups according to the drug received; 2) identiﬁ-
cation of VLTPR based on ROC curve analysis; 3) incidence
of VLTPR and predictors of VLTPR in the whole population
and in different groups according to the drug received; and
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8564) incidence of deﬁnite and probable stent thrombosis
according to different groups of platelet reactivity: VLTPR,
HTPR, and patients with “normal” platelet reactivity.
Statistical analysis. Statistical analyses were performed using
PASW Statistics version 17.0 (SPSS Inc, Chicago, Illinois).
Continuous variables were reported as mean and SD or as
median and range (according to their distribution), and
categorical variables were reported as count and percentage.
Univariate and multivariate analyses were performed using
a logistic regression model. One-way analysis of variance was
used for comparison of different groups. Odds ratios (ORs)
were estimated with a 95% conﬁdence intervals (CIs). Cali-
bration of the logistic model was assessed using the Hosmer-
Lemeshow goodness-of-ﬁt test. Areas under the ROC curves
(AUCs) were determined using MedCalc Software version
12.3.0 (MedCalc Software, Mariakerke, Belgium). For all
tests, statistical signiﬁcance was deﬁned as p < 0.05.
Assuming that occurrence of bleeding will be 20% in the
whole population and expecting in these patients a 5%
absolute difference in PRI VASP compared with non bleeder
patients, a total of at least 800 patients were needed in both
groups to detect the expected difference with an estimated
power of 80% with a 2-sided alpha of 0.05.
Results
A total of 1,663 consecutive patients undergoing PCI with
coronary stenting for ACS were discharged from our insti-
tution. Among these patients, 21 declined to participate
in the study, and at 21 month, 91 patients were lost to
follow-up (platelet testing not available), and 9 patients died
between hospital discharge and 1 month follow-up.
Therefore, 1,542 patients were included in the present study
(287 receiving clopidogrel 75 mg, 868 receiving clopidogrel
150 mg, and 387 receiving prasugrel 10 mg) (Fig. 1).
Ninety-one percent of the patients underwent PCI via radial
access. For co-medications affecting bleeding complications,
none of the patients received cilostazol or nonsteroidal anti-
inﬂammatory drugs, and a proton pump inhibitor was
prescribed at discharge for all patients.Figure 1. Flowchart of the Present StudyBleeding complications: identiﬁcation of the VLTPR and
predictors of bleeding. In the whole population, 9% patients
(139/1,542) experienced bleeding complications during 6-
month follow-up, including 67 BARC 1, 52 BARC 2, and
20 BARC 3 bleeding, including 8 life-threatening and 3
intracranial bleeding events. The rate of bleeding was
signiﬁcantly higher in patients treated by prasugrel 10 mg
compared with patients treated with clopidogrel 75 or 150
mg (16% [61 of 387] vs. 7% [78 of 1,155]; OR: 2.6, 95% CI:
1.8 to 3.7; p < 0.0001). In the whole population, patients
with bleeding had lower PRI VASP values than patients
without bleeding: 27  17% vs. 41  19%, p < 0.001
(Fig. 2). This association between PRI VASP and bleeding
was observed in all 3 groups (clopidogrel 75 mg, clopidogrel
150 mg, and prasugrel 10 mg): 40  21% vs. 49  19%, p ¼
0.02; 28  17% vs. 43  18%, p < 0.001 and 21  13% vs.
29  13%, p < 0.001, respectively (Fig. 2).
In the whole population, ROC analysis was performed to
deﬁne the best PRI VASP value for prediction of bleeding
complications (AUC ¼ 0.71, p < 0.0001) (Fig. 3). We
chose a threshold value of PRI VASP 10% to predict
bleeding complications with a sensitivity of 17%, a speciﬁcity
of 97%, a positive predictive value of 33.3%, and a negative
predictive value of 92% (Fig. 2). This value of PRI VASP
10% was deﬁned as VLTPR.
Characteristics of the patients with or without bleeding
were compared in the whole population and in each group
according to the therapy (Table 1). The rate of patients
treated with GPI (glycoprotein IIb/IIIa inhibitors) was not
different among bleeders and nonbleeders: 35% (48 of 139)
vs. 31% (435 of 1,403); p > 0.05.
In the whole population (N ¼ 1,542), variables associ-
ated with the risk of bleeding on univariate analysis were
female sex more frequent in bleeders (32% [n ¼ 44] vs.
19% [n ¼ 261], p < 0.001), diabetes less frequent in
bleeders (19% [n ¼ 26) vs. 31% [n ¼ 436], p < 0.01),
treatment by prasugrel more frequent in bleeders (44%
[n ¼ 61] vs. 23% [n ¼ 326], p < 0.001), and VLTPR (PRI
VASP 10%) more frequent in bleeders (17% [n ¼ 23] vs.
3.5% [n ¼ 46], p < 0.001). On multivariate analysis, the
remaining factors associated with bleeding were female sex
(OR: 2.7, 95% CI: 1.8 to 4.1; p < 0.001), absence of
diabetes (OR: 1.9, 95% CI: 1.2 to 3.1; p ¼ 0.005), treat-
ment by prasugrel (OR: 1.8, 95% CI: 1.1 to 2.9; p ¼ 0.03),
and VLTPR (OR: 4.7, 95% CI: 2.7 to 8.3; p < 0.001)
(Table 2). VLTPR (PRI VASP 10%) was the strongest
predictor of bleeding regardless of whether the patient was
receiving thienopyridine.
In the group of patients treated with clopidogrel 75 mg
(n ¼ 289), the only variable in the univariate analysis asso-
ciated with bleeding was the PRI VASP with lower values in
patients with bleeding: 40  21% vs. 49  19%, p ¼ 0.02.
This association remained signiﬁcant on multivariate anal-
ysis: OR: 0.98, 95% CI: 0.96 to 0.99; p ¼ 0.04. Due to
Figure 2. Relationship Between Platelet Reactivity and Bleeding Events
Platelet reactivity index vasodilator-stimulated phosphoprotein (PRI VASP) values in patients with or without bleeding in the whole population and in the 3 groups
treated by clopidogrel 75 mg, clopidogrel 150 mg, or prasugrel 10 mg.
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857a very low incidence of VLTPR in the population treated
with clopidogrel 75 mg (1%), this marker was not signiﬁ-
cantly associated with the risk of bleeding.
In the group of patients treated with clopidogrel 150 mg
(n ¼ 868), variables associated with the risk of bleeding in
the univariate analysis were female sex more frequent in
bleeders (17% [n ¼ 9] vs. 5% [n ¼ 33], p ¼ 0.03), diabetes
less frequent in bleeders (10% [n ¼ 5] vs. 32% [n ¼ 261],
p < 0.01), smaller waist circumference in bleeders (93  13
cm vs. 99  12 cm, p ¼ 0.001), smoking more frequent in
bleeders (50% [n ¼ 25] vs. 34% [n ¼ 279], p ¼ 0.02) and
VLTPR (PRI VASP 10%) more frequent in bleeders
(21% [n ¼ 9] vs. 3% [n ¼ 21], p < 0.001). On multivariate
analysis, the remaining factors associated with bleeding were
waist circumference (OR: 0.97, 95% CI: 0.94 to 0.99;
p ¼ 0.01), absence of diabetes (OR: 3.5, 95% CI: 1.2 to
10.2; p ¼ 0.02), and VLTPR (OR: 8.0, 95% CI: 3.2 to 20.5;
p < 0.001) (Table 2). VLTPR (PRI VASP 10%) was the
strongest predictor of bleeding in patients treated by clopi-
dogrel 150 mg.
In the group of patients treated with prasugrel 10 mg
(n ¼ 387), variables associated with the risk of bleedingwere, on univariate analysis, female sex more frequent in
bleeders (39% [n ¼ 16] vs. 13% [n ¼ 45], p < 0.001),
diabetes less frequent in bleeders (21% [n ¼ 13] vs. 32%
[n ¼ 261], p ¼ 0.06), treatment for STEMI less frequent in
bleeders (30% [n ¼ 18] vs. 46% [n ¼ 150], p ¼ 0.02), and
VLTPR (PRI VASP 10%) more frequent in bleeders
(21% [n ¼ 13] vs. 7% [n ¼ 23], p < 0.001). On multivariate
analysis, the remaining factors associated with bleeding were
female sex (OR: 5.1, 95% CI: 2.4 to 4.8; p< 0.001), absence
of diabetes (OR: 2.4, 95% CI: 1.2 to 4.8; p ¼ 0.02), and
VLTPR (OR: 3.7, 95% CI: 1.7 to 8.1; p < 0.001) (Table 2).
Again, VLTPR (PRI VASP 10%) was the strongest
predictor of bleeding in patients treated with prasugrel 10
mg, as observed for clopidogrel 150 mg.
Stent thrombosis and relationship with platelet parameters. A
total of 463 patients (30%) were identiﬁed withHTPR. In the
whole population, during the 6-month follow-up, 34 patients
experienced deﬁnite or probable stent thrombosis. These
patients had signiﬁcantly higher platelet reactivity: PRIVASP
48  21% vs. 39  19%, p ¼ 0.02. The rates of deﬁnite and
probable stent thrombosis among the different groups were
4% in patients with HTPR (19 of 463), 1.4% in patients with
Figure 3. Determination of Very Low On-Treatment Platelet Reactivity With
Receiver-Operating Characteristic Analysis
Receiver-operating characteristic curve analysis of the relationship between
bleeding and platelet reactivity index vasodilator-stimulated phosphoprotein
(VASP) (area under the curve ¼ 0.71, p < 0.001). Identiﬁcation of very low on-
treatment platelet reactivity as platelet reactivity index VASP 10% for the
prediction of bleeding events (sensitivity, 17%; speciﬁcity, 97%).
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858normal platelet reactivity (10% < PRI VASP <50%) (14 of
1,010) and 1.4% (1 of 69) in patients with VLTPR (p ¼
0.004).
Incidence and predictors of VLTPR and net clinical beneﬁt.
VLTPR (PRI VASP 10%) has been identiﬁed as the
strongest predictor of bleeding complications in the whole
population and in the groups of patients treated with clo-
pidogrel and prasugrel. Indeed, patients with VLTPR had
a higher rate of bleeding complications in the whole pop-
ulation and in the group of patients treated with clopidogrel
or prasugrel: 33% (n ¼ 23 of 69) vs. 8% (n ¼ 112 of 1,473)
(OR: 6.1, 95% CI: 3.5 to 10.4; p < 0.001), 30% (n ¼ 10 of
33) vs. 6% (n ¼ 68 of 1,122) (OR: 6.7, 95% CI: 3.1 to 14.7;
p < 0.001) and 36% (n ¼ 13 of 36) vs. 14% (n ¼ 48 of 351)
(OR: 3.6, 95% CI: 1.7 to 7.5; p ¼ 0.001), respectively
(Figs. 4A and 4B). Including only the BARC bleeding 2,
this association remained signiﬁcant in the whole population
with a higher incidence of BARC bleeding 2 in patients
with VLTPR: 16% (n ¼ 11 of 69) vs. 4% (n ¼ 61 of 1,473)
(OR: 4.4, 95% CI: 2.2 to 8.8; p < 0.001). By pooling stent
thrombosis and BARC bleeding 2 in the 3 groups of
patients (HTPR [PRI VASP >50%], normal platelet reac-
tivity [10% > PRI VASP >50%], and VLTPR [PRI VASP
10%]), the rates of this combined endpoint were 8% for
patients with HTPR (4% stent thrombosis, 4% BARCbleeding 2), 5.7% in patients with normal platelet reac-
tivity (1.4% stent thrombosis, 4.3% BARC bleeding 2),
and 17.4% in patients with VLTPR (1.4% stent thrombosis
and 16% BARC bleeding 2). Patients with normal platelet
reactivity within the therapeutic window had a signiﬁcantly
lower events rate than other patients with HTPR or
VLTPR: 5.7% (57/1,010) vs. 9.2% (49/532) (OR: 1.7, 95%
CI: 1.1 to 2.5; p ¼ 0.009). This association remains
signiﬁcant on multivariate analysis after adjustment for
confounding variables (p ¼ 0.02).
The incidence of VLTPR in the whole population was
4.5% (69 of 1,542) with a stepwise increase in the 3 groups
of clopidogrel 75 mg, clopidogrel 150 mg, and prasugrel
10 mg: 1% (3 of 287), 3.5% (30 of 868), and 9% (36 of 387),
respectively, p < 0.001 (Fig. 5).
Characteristics of the patients with or without VLTPR
(VASP 10%) were compared in the whole population and
in each group according to the therapy (Table 3).
In the whole population (N ¼ 1,542), variables associated
with VLTPR on univariate analysis were younger patients
(61  12 years of age vs. 64  13 years of age, p ¼ 0.02),
lower body mass index (BMI) (26  5 kg/m2 vs. 27  4 kg/
m2, p ¼ 0.03), higher incidence of family history (36% [n ¼
25] vs. 26% [n ¼ 376], p ¼ 0.048), dyslipidemia (67% [n ¼
46] vs. 55% [n ¼ 807], p ¼ 0.05), smoking (51% [n ¼ 35]
vs. 36% [n ¼ 528], p ¼0.01), lower incidence of hyperten-
sion (44% [n ¼ 30] vs. 58% [n ¼ 856], p ¼ 0.02), diabetes
mellitus (18% [n ¼ 12] vs. 31% [n ¼ 450], p ¼ 0.02), and
treatment with prasugrel (52% [n ¼ 36] vs. 24% [n¼ 351], p
< 0.001). On multivariate analysis, the remaining factors
associated with VLTPR were dyslipidemia (OR: 2.2; 95%
CI: 1.3 to 3.8; p ¼ 0.004) and treatment with prasugrel (OR:
10.2; 95% CI: 3 to 34.2; p < 0.001) (Table 4). Treatment
with prasugrel was the strongest predictor of VLTPR in the
global population.
In the group of patients treated with clopidogrel 75 mg
(n ¼ 289), due to the very low incidence of VLTPR (1%),
none of the baseline characteristics were signiﬁcantly asso-
ciated with the risk of VLTPR (Table 3).
In the group of patients treated with clopidogrel 150 mg
(n ¼ 868), variables associated with the risk of VLTPR on
univariate analysis were higher incidence of family history
(50% [n ¼ 15] vs. 26% [n ¼ 214], p ¼ 0.003), dyslipidemia
(83% [n ¼ 23] vs. 56% [n ¼ 466], p ¼ 0.003), and smoking
(60% [n ¼ 18] vs. 34% [n ¼ 286], p ¼ 0.004) (Table 3). On
multivariate analysis, the remaining factors associated with
VLTPR were family history (OR: 2.8, 95% CI: 1.3 to 5.8;
p ¼ 0.007) and smoking (OR: 2.8, 95% CI: 1.4 to 6.1;
p ¼ 0.007) (Table 4).
In the group of patients treated with prasugrel 10 mg
(n ¼ 387), variables associated with the risk of VLTPR on
univariate analysis were lower BMI (25  4 kg/m2 vs. 28 
4 kg/m2, p ¼ 0.001), smaller waist circumference (95  10
cm vs. 101  12 cm, p ¼ 0.004), and treatment for STEMI
Table 1. Baseline Characteristics and Platelet Parameters in Patients With or Without Bleeding in the Whole Population and the 3 Groups Treated With Clopidogrel 75 mg, Clopidogrel 150 mg,
or Prasugrel 10 mg
Total Population Clopidogrel 75 mg Clopidogrel 150 mg Prasugrel 10 mg
No Bleeding
(n ¼ 1,403)
Bleeding
(n ¼ 139) p Value
No Bleeding
(n ¼ 259)
Bleeding
(n ¼ 28) p Value
No Bleeding
(n ¼ 818)
Bleeding
(n ¼ 50) p Value
No Bleeding
(n ¼ 326)
Bleeding
(n ¼ 61) p Value
Age, yrs 64 13 64  12 0.66 68  13 72  11 0.09 65  13 62  11 0.07 58  10 61  10 0.04
Female 26 (19) 44 (32) <0.001 17 (8) 11 (14) 0.13 33 (5) 17 (9) 0.03 45 (13) 16 (39) <0.001
BMI, kg/m2 27  4 27  4 0.35 26  4 27  4 0.55 27  4 26  5 0.17 27  4 27  5 0.33
Waist circumference, cm 99  12 97  13 0.06 98  12 98  11 0.82 99  12 93  13 0.001 100  12 100  13 0.97
Family history of CAD 368 (26) 33 (24) 0.52 57 (22) 8 (29) 0.43 216 (26) 13 (26) 0.95 95 (29) 12 (20) 0.13
Hypertension 812 (58) 74 (53) 0.29 154 (60) 19 (68) 0.39 517 (63) 28 (56) 0.31 141 (43) 27 (44) 0.88
Diabetes mellitus 436 (31) 26 (19) 0.002 68 (26) 8 (29) 0.79 261 (32) 5 (10) 0.001 107 (33) 13 (21) 0.06
Dyslipidemia 779 (56) 74 (53) 0.61 140 (54) 16 (57) 0.76 469 (57) 22 (44) 0.07 170 (52) 36 (59) 0.32
Smoking 504 (36) 59 (42) 0.13 78 (30) 9 (32) 0.83 279 (34) 25 (50) 0.02 147 (45) 25 (41) 0.13
Treatment for STEMI 416 (30) 42 (30) 0.89 68 (26) 9 (32) 0.51 198 (24) 15 (30) 0.36 150 (46) 18 (30) 0.02
Ejection fraction, % 55  8 56  7 0.18 54  10 54  7 0.69 55  8 57  7 0.09 55  7 55  8 0.86
Creatinine, mmol 96  69 94  68 0.81 107  99 86  29 0.29 95  63 105  106 0.52 89  49 89  34 0.99
PRI VASP, % 41  19 27  17 <0.0001 49  19 40  21 0.02 43  18 28  17 <0.0001 29  13 31  13 <0.001
VLTPR (VASP 10%) 46 (3.5) 23 (17) <0.0001 2 (0.8) 1 (4) 0.28 21 (3) 9 (21) <0.0001 23 (7) 13 (21) <0.001
Clopidogrel, 75 mg 259 (19) 28 (20) <0.001
Clopidogrel 150 mg 818 (58) 50 (36)
Prasugrel 10 mg 326 (23) 61 (44)
Values are mean  SD or n (%).
BMI ¼ body mass index; CAD ¼ coronary artery disease; PRI VAS ¼ platelet reactivity index vasodilator-stimulated phosphoprotein; STEMI ¼ ST-segment elevation myocardial infarction; VLTPR ¼ very low on-treatment platelet reactivity.
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Figure 4. Relationship Between Bleeding and Very Low On-Treatment
Platelet Reactivity
(A) Incidence of bleeding complications among patients with or without very
low on-treatment platelet reactivity (VLTPR) (platelet reactivity index vasodi-
lator-stimulated phosphoprotein 10%) during the 6-month follow-up. (B)
Impact of VLTPR on incidence of bleeding complications. CI ¼ conﬁdence
interval; OR ¼ odds ratio.
Table 2. Multivariate Analysis for Identiﬁcation of Predictors of Bleeding in the Whole Population
and the 3 Groups Treated With Clopidogrel 75 mg, Clopidogrel 150 mg, or Prasugrel 10 mg
Factors Associated With Bleeding Complications on Multivariate Analysis
Characteristics OR (95% CI) p Value
Total population
(N ¼ 1,542)
Female 2.7 (1.8–4.1) <0.001
Nondiabetic 1.9 (1.2–3.1) 0.005
Prasugrel 1.8 (1.1–2.9); 0.03
VLTPR (VASP 10%) 4.7 (2.7–8.3) <0.001
Clopidogrel 75 mg
(n ¼ 287)
PRI VASP* 0.98 (0.96–0.99) 0.04
Clopidogrel 150 mg
(n ¼ 868)
Waist circumference* 0.97 (0.94–0.99) 0.01
Nondiabetic 3.5 (1.2–10.2) 0.02
VLTPR (VASP 10%) 8 (3.2–20.5) <0.001
Prasugrel 10 mg
(n ¼ 387)
Female 5.1 (2.4–10.7) <0.001
Nondiabetic 2.4 (1.2–4.8) 0.02
VLTPR (VASP 10%) 3.7 (1.7–8.1) <0.001
*Per unit.
CI ¼ conﬁdence interval; OR ¼ odds ratio; PRP VASC ¼ platelet reactivity index vasodilator-stimulated phosphoprotein; VLTPR ¼ very low
on-treatment platelet reactivity.
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860less frequent in patients with VLTPR (31% [n ¼ 11] vs.
45% [n ¼ 157], p ¼ 0.09). On multivariate analysis, the
remaining factors associated with incidence of VLTPR were
BMI (OR: 0.87, 95% CI: 0.76 to 0.99; p ¼ 0.04) and initial
presentation different than STEMI (OR: 2.6, 95% CI: 1.2
to 5.6; p ¼ 0.02) (Table 4).
Discussion
In the present study, we observed the following: 1. a signiﬁ-
cant relationship between platelet reactivity and bleeding
events in patients treated with thienopyridines; 2. that
VLTPR deﬁned as PRI VASP 10% was the strongest
predictor of bleeding regardless of background therapy; 3.
bleeding on thienopyridines was more frequent in women
and nondiabetic patients; and 4. VLTPR was mainlyFigure 5. Incidence of Very Low On-Treatment Platelet Reactivity
(Vasodilator-Stimulated Phosphoprotein 10%) According to
Thienopyridine Therapy
Incidence of very low on-treatment platelet reactivity (vasodilator-stimulated
phosphoprotein 10%) in patients treated by clopidogrel 75 mg, clopidogrel
150 mg, and prasugrel 10 mg.
Table 3. Baseline Characteristic and Platelet Parameters Among Patients With or Without VLTPR (PRI VASP 10%) in the Whole Population and the 3 Groups Treated With Clopidogrel 75 mg,
Clopidogrel 150 mg, or Prasugrel 10 mg
Total Population Clopidogrel 75 mg Clopidogrel 150 mg Prasugrel 10 mg
No VLTPR
(n ¼ 1,473)
VLTPR
(n ¼ 69) p Value
No Bleeding
(n ¼ 259)
Bleeding
(n ¼ 28) p Value
No Bleeding
(n ¼ 818)
Bleeding
(n ¼ 50) p Value
No Bleeding
(n ¼ 326)
Bleeding
(n ¼ 61) p Value
Age 64  13 61  12 0.02 69  13 72  8 0.68 65  13 63  12 0.42 59  10 58  11 0.58
Female 293 (20) 12 (17) 0.61 17 (8) 11 (14) 0.13 178 (21) 8 (27) 0.48 38 (11) 3 (11) 1.0
BMI, kg/m2 27  4 26  4 0.03 26  4 22  3 0.08 27  4 27  5 0.89 28  4 25  4 0.001
Waist circumference, cm 99  12 96  12 0.07 98  12 89  7 0.08 99  13 99  13 0.92 101  12 95  10 0.004
Familial history 376 (26) 25 (36) 0.05 65 (23) 0 (0) 1.0 214 (26) 15 (50) 0.003 97 (28) 10 (28) 0.99
Hypertension 856 (58) 30 (44) 0.02 171 (60) 2 (67) 1.0 528 (63) 17 (57) 0.48 157 (45) 11 (31) 0.10
Diabetes mellitus 450 (31) 12 (18) 0.02 76 (27) 0 (0) 0.57 261 (31) 5 (17) 0.09 113 (32) 7 (19) 0.12
Dyslipidemia 807 (55) 46 (67) 0.05 154 (54) 2 (67) 1.0 466 (56) 25 (83) 0.003 187 (53) 19 (53) 0.95
Smoking 528 (36) 35 (51) 0.01 87 (31) 0 (0) 0.56 286 (34) 18 (60) 0.004 155 (44) 17 (47) 0.73
Treatment for STEMI 436 (30) 22 (32) 0.69 75 (26) 2 (67) 0.51 204 (24) 9 (30) 0.48 157 (45) 11 (31) 0.09
Ejection fraction, % 55  8 56  6 0.21 54  9 50  13 0.18 55  8 56  6 0.09 55  7 55  6 0.98
Creatinine, mmol 96  70 88  25 0.37 105  95 93  23 0.83 96  67 88  27 0.52 89  49 88  23 0.91
Clopidogrel 75 mg 284 (19) 3 (4) <0.001
Clopidogrel 150 mg 838 (57) 30 (44)
Prasugrel 10 mg 351 (24) 36 (52)
Values are mean  SD or n (%).
Abbreviations as in Table 1.
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Table 4. Multivariate Analysis for Identiﬁcation of Predictors of VLTPR in the Whole Population
and in the 3 Groups Treated by Clopidogrel 75 mg, Clopidogrel 150 mg, or Prasugrel 10 mg
Factors Associated With VLTPR on Multivariate Analysis
Characteristics OR (95% CI) p Value
Total population
(n ¼ 1,542)
Age 2.2 (1.3–3.8) 0.004
Prasugrel 10.2 (3–34.2) <0.0001
Clopidogrel 150 mg
(n ¼ 868)
Family history 2.8 (1.3–5.8) 0.007
Smoking 2.8 (1.4–6.1) 0.007
Prasugrel 10 mg
(n ¼ 387)
BMI 0.87 (0.76–0.99) 0.04
Presentation other than STEMI 2.6 (1.2–5.6) 0.02
*Per unit.
Abbreviations as in Tables 1 and 2.
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862observed with prasugrel, less frequent with high-dose clopi-
dogrel, and very rare with standard clopidogrel 75 mg.
The clinical relevance of platelet function testing has been
demonstrated in different clinical settings for both ischemic
(7–11) and bleeding (12,13) complicationswith clopidogrel and
for bleeding complications with prasugrel (19,20). This asso-
ciation between on-treatment platelet inhibition and bleeding
complications has also been observed in the large TRITON-
TIMI (Trial to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition with Prasugrel–Thrombol-
ysis in Myocardial Infarction) (5) and PLATO (PLATelet
inhibition andpatientOutcomes) (6) studieswheremorepotent
drugs provided a higher rate of bleeding events (5,6). The
present study demonstrated that P2Y12 pathway inhibition
assessed by PRI VASP was the strongest predictor of bleeding
complications. These results suggest PRI VASP as the best
option for bleeding risk prediction in patients treated with
clopidogrel and prasugrel. Indeed, it is interesting to note that
light transmittance aggregometry is rarely below 20% in
previous study (19) whereas PRI VASP may reach 0% indi-
cating a limit of light transmittance aggregometry to detect
a strong degree of P2Y12 inhibition (19). Therefore, PRIVASP
appears as a better option for the assessment of platelet response
and bleeding risk in patients treated with strong P2Y12 inhib-
itors. In the present study, we includedBARC1 bleeding in the
analysis. These bleeding complications might not be clinically
meaningful by themselves and could be considered minimal or
nuisance bleedings. However, these events might lead to
premature discontinuation of the drug in daily practice, as
shown in clopidogrel- and prasugrel-treated patients (23,24)
and should be included in the analysis. Although including
only the BARC bleeding2, the association between VLTPR
and clinical outcomes remained signiﬁcant in the present study.
In the whole population and the different subgroups,
bleeding occurredmore frequently inwomen.These results are
in line with previous ﬁndings from the GRACE (Global
Registry of Acute Coronary Events) registry, showing that
female sex was independently associated with a higher risk of
bleeding after ACS (25). This might suggest that more potentdrugs should be used with caution in this speciﬁc population.
In the prasugrel-treated patients, the incidence of bleeding and
VLTPR was lower in diabetic patients and patients treated for
STEMI. These results are in line with subgroup analyses from
the TRITON study, showing a greater ischemic beneﬁt
without bleeding hazard in these 2 populations (26,27). In the
clopidogrel-treated patients, diabetes was also found to be
associated with a lower risk of bleeding complications. This
ﬁnding is in line with previous studies showing impaired clo-
pidogrel response in diabetic patients (28,29). We also
observed that the incidence of VLTPR in clopidogrel-treated
patients was higher in smokers. This could be explained by
higher cytochrome P450 activity in smokers (30), resulting in
greater clopidogrel efﬁcacy due to better biotransformation
into its active metabolite, as previously described (31).
Study limitations. The main limitation of the present study is
its limited sample size and the lack of power to detect effect on
endpoints such as mortality related to bleeding. Also, the
assessment of the response to long-term antiplatelet therapy
may have been modiﬁed by a lack of compliance. However, in
the present study, efforts were made to improve compliance
and to detect noncompliant patients.Conclusions
The present study showed that the degree of P2Y12 pathway
inhibition is crucial for prediction of bleeding complications
and is independent of the treatment drug received. The
results suggest a potential beneﬁt of tailored therapy for
bleeding prevention, with a switch to a less potent therapy in
patients with strong P2Y12 pathway inhibition. This
hypothesis should be tested in a large randomized study. In
this perspective, the ongoing ANTARCTIC (Tailored
Antiplatelet Therapy Versus Recommended Dose of Pra-
sugrel) study (NCT01538446), focusing on elderly patients,
is targeting a therapeutic window to lower both type of
recurrent events in this high-risk population and assess the
net clinical beneﬁt of this strategy.
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